ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meeting Abstracts
    • All Meetings
    • ACR Convergence 2026
    • PRSYM 2026
    • ACR Convergence 2025
    • Download Abstract Supplements
  • Keyword Index
  • My Favorites
    • View & print my favorites
  • Search

Home » Meeting Abstracts » ACR Convergence 2024

Abstract Number: 2027

Clinical Features and Treatment of Retroperitoneal Fibrosis in a Referral Hospital and Literature Review

Adrián Martín-Gutiérrez1, Javier Loricera2, Fernando Lopez-Gutierrez3 and Ricardo Blanco-Alonso4, 1Hospital Universitario Marques de Valdecilla, IDIVAL, Renedo de Piélagos, Cantabria, Spain, 2Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, Spain, 3Rheumatology, Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, Cantabria, Spain, 4Division of Rheumatology, Hospital Universitario Marqués de Valdecilla. IDIVAL, Immunopathology group, Santander, Spain

Share on X (Twitter) Share on Facebook Share on LinkedIn Share on Email
Print

Meeting: ACR Convergence 2024

Keywords: Fibrosing syndromes, glucocorticoids, IgG4 Related Disease

Session Information

Date: Monday, November 18, 2024

Title: Miscellaneous Rheumatic & Inflammatory Diseases Poster III

Session Type: Poster Session C

Session Time: 10:30AM-12:30PM

Background/Purpose: Retroperitoneal fibrosis (RPF) is usually idiopathic (iRPF), but may be secondary to drugs, neoplasms, infections, or may be part of an IgG4-related disease.
Our aim was to evaluate the clinical features, analytical features, imaging findings and treatment modalities in patients with RPF.

Methods: Patients diagnosed with RPF in a referral hospital between 2000 and 2023. For the literature review, we searched PubMed and the Cochrane library from its inception until 31 December 2023, selecting those series with the largest number of patients.

Results: We present 26 patients (11 females/15 males) with RPF. The mean±SD age of the patients at diagnosis was 59.7±12.4 years. Seventeen patients had an iRPF. In the remaining 9 patients, RPF was secondary to: neoplasia (n=5; 19%), radiotherapy (n=2; 8%), acute pancreatitis (n=1; 4%), IgG4-related disease (n=1; 4%). The main characteristics of the patients are listed in the Figure 1. Fifty percent of the patients were smokers or ex-smokers. Abdominal pain (65%) and low back pain (42%) were the most frequent manifestations. Elevation of acute phase reactants was observed in 15/20 (75%) patients and worsening renal function in 10/25 (40%) patients. In the literature review, 4 series of more than 50 patients each were selected. The main data from the different series are listed in Figure 1. The diagnosis of RPF was made by ultrasounds (n=16; 61%), CT (n=24; 92%), MRI (n=2; 8%), PET/CT (n=6; 23%). The most frequent pattern of involvement was periaortic-periiliac (50%) and hydronephrosis (50%) (Figure 2A). Glucocorticoids were the most frequent medical treatment (69%). The most frequent interventional procedure was ureteral stenting (38%) (Figure 2B).

Conclusion: RPF is a rare entity that may be idiopathic or secondary to other processes. Abdominal pain and abdominal pain are frequent manifestations. Glucocorticoids are the medical treatment of choice and ureteral stenting is the most commonly used interventional procedure.

Supporting image 1

Abbreviations: CRP: C-reactive protein, ESR: erythrocyte sedimentation rate, IQR: interquartile range, ND: no data, RPF: retroperitoneal fibrosis, SD: standard deviation.

Supporting image 2


Disclosures: A. Martín-Gutiérrez: None; J. Loricera: AstraZeneca, 2, 6, Celgene, 2, 6, Eli Lilly, 5, Janssen, 5, Merck/MSD, 2, 5, 6, Novartis, 12, Formation/Congress attendance, Pfizer, 5, Roche, 2, 5, 6, UCB, 2, 5, 6; F. Lopez-Gutierrez: AstraZeneca, 12, Formation/Congress attendance, 12, Formation/Congress attendance, Novartis, 12, Formation/congress attendance; R. Blanco-Alonso: AbbVie, 2, 5, 6, Bristol-Myers Squibb, 2, 6, Galapagos, 6, Janssen, 2, 6, Lilly, 2, 6, MSD, 2, 5, 6, Pfizer, 2, 6, Roche, 2, 5, 6.

To cite this abstract in AMA style:

Martín-Gutiérrez A, Loricera J, Lopez-Gutierrez F, Blanco-Alonso R. Clinical Features and Treatment of Retroperitoneal Fibrosis in a Referral Hospital and Literature Review [abstract]. Arthritis Rheumatol. 2024; 76 (suppl 9). https://acrabstracts.org/abstract/clinical-features-and-treatment-of-retroperitoneal-fibrosis-in-a-referral-hospital-and-literature-review/. Accessed .

ACR Meeting Abstracts - https://acrabstracts.org/abstract/clinical-features-and-treatment-of-retroperitoneal-fibrosis-in-a-referral-hospital-and-literature-review/

My Favorites

Save and print abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract (must have cookies enabled in browser). See saved favorites.

Abstract Policies

  • ACR Convergence Abstract Embargo Policies
  • ACR Convergence Abstract Permissions & Reprints
  • PRSYM Abstract Policies

ACR Convergence. Where Rheumatology Meets

ACR Convergence 2026

Join us November 6-11 in Orlando, Florida.
See Registration Information

  • Contact ACR
  • Privacy Policy
  • ACR Policies
  • Cookie Preferences

© Copyright 2026 American College of Rheumatology